Skip to content
Benefits & EvidenceEvidence-Tiered

Anamorelin Benefits

What does Anamorelin actually do? We break down the evidence by tier — human data, animal studies, and in vitro research — with citations for every claim.

Quick Answer

Anamorelin's primary benefit is to preserve lean body mass and stimulate appetite in cancer cachexia patients. Clinical trials demonstrate an increase in lean body mass compared to placebo, along with improved appetite and increased growth hormone levels. These effects contribute to enhanced quality of life.

Evidence Tiers

HumanClinical or observational human dataAnimalPreclinical in vivo studiesIn VitroCell / tissue culture studies

Mechanism of Action

Anamorelin activates the ghrelin receptor (GHS-R1a), mimicking ghrelin's effects on appetite and growth hormone secretion. This leads to increased food intake, reduced satiety, and enhanced anabolic processes. In cancer cachexia, where inflammatory cytokines suppress appetite and promote muscle breakdown, anamorelin counteracts these effects.

Human Evidence

Human3 findings

Lean body mass gain

The ROMANA trials demonstrated statistically significant increases in lean body mass compared to placebo in patients with cancer cachexia.

PubMed 25908441 (2015) ↗

Appetite stimulation

Anamorelin significantly improved appetite scores and food intake in patients with cancer-related anorexia.

PubMed 28427718 (2017) ↗

Growth hormone elevation

Anamorelin increases growth hormone and IGF-1 levels, restoring anabolic hormone balance disrupted by cancer.

PubMed 25908441 (2015) ↗

Animal Studies

Animal2 findings

Increased food intake

Animal studies have shown that anamorelin increases food intake and promotes weight gain.

PubMed 16880240 (2006) ↗

Improved body composition

Animal models demonstrate improved body composition with increased lean mass and reduced fat mass following anamorelin treatment.

PubMed 18682464 (2008) ↗

In Vitro Research

In Vitro2 findings
In vitro (cell culture) findings are the earliest stage of evidence. They indicate mechanism plausibility but cannot confirm human effects.

Ghrelin receptor activation

In vitro studies confirm anamorelin's potent agonist activity at the ghrelin receptor (GHS-R1a).

PubMed 15466562 (2004) ↗

Growth hormone secretion

Cell culture experiments show that anamorelin stimulates growth hormone secretion from pituitary cells.

PubMed 15466562 (2004) ↗

What's Proven vs What's Still Unknown

✓ What the Evidence Supports

  • Lean body mass preservation in cancer cachexia patients
  • Appetite stimulation in cancer-related anorexia
  • Growth hormone and IGF-1 elevation
  • Oral convenience and ease of administration

? Still Unknown or Unconfirmed

  • ?Long-term effects on survival in cancer patients
  • ?Efficacy in non-cancer wasting conditions
  • ?Optimal duration of treatment for different patient populations

Frequently Asked Questions

What are the primary benefits of anamorelin?
The main benefits are lean body mass preservation, appetite stimulation, and increased growth hormone levels in cancer cachexia patients.
How does anamorelin improve appetite?
Anamorelin mimics ghrelin, activating the ghrelin receptor in the hypothalamus, which stimulates appetite and reduces satiety.
Does anamorelin improve survival in cancer patients?
The ROMANA trials were not designed to assess survival, and no statistically significant survival benefit has been demonstrated. However, it may improve quality of life.
Can anamorelin be used for other conditions?
Anamorelin is approved only for cancer cachexia. Its use for other conditions is off-label and requires further research.
How quickly does anamorelin work?
Improvements in appetite and lean body mass may be observed within a few weeks of starting anamorelin, as demonstrated in the ROMANA trials.

References

  1. 1
    Anamorelin for patients with cancer cachexia: ROMANA 1 and ROMANA 2 phase 3 trials(2015)PubMed ↗
  2. 2
    Anamorelin for the treatment of cancer anorexia-cachexia: ROMANA 3 extension trial(2017)PubMed ↗
  3. 3
    Ghrelin receptor agonists for cancer cachexia: a systematic review and meta-analysis(2021)PubMed ↗

Last updated: 2026-02-19